for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AbbVie Inc

ABBV.N

Latest Trade

109.33USD

Change

0.42(+0.39%)

Volume

1,901,964

Today's Range

109.09

 - 

109.95

52 Week Range

79.12

 - 

121.53

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
108.91
Open
109.15
Volume
1,901,964
3M AVG Volume
152.22
Today's High
109.95
Today's Low
109.09
52 Week High
121.53
52 Week Low
79.12
Shares Out (MIL)
1,767.18
Market Cap (MIL)
193,205.30
Forward P/E
8.64
Dividend (Yield %)
4.76

Next Event

Q3 2021 Abbvie Inc Earnings Release

Latest Developments

More

Abbvie Receives CHMP Positive Opinion For Risankizumab For The Treatment Of Psoriatic Arthritis

Eurobio Scientific Receives USD 430,000 Milestone Payment From Allergan

AbbVie Says FDA Approves Qulipta, Developed For Preventive Treatment Of Migraine

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AbbVie Inc

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.

Industry

Biotechnology & Drugs

Contact Info

1 N Waukegan Rd

NORTH CHICAGO, IL

60064-1802

United States

+1.847.9327900

https://www.abbvie.com/

Executive Leadership

Richard A. Gonzalez

Chairman of the Board, Chief Executive Officer

Michael E. Severino

President, Vice Chairman

Laura J. Schumacher

Vice Chairman, External Affairs and Chief Legal Officer

Robert A. Michael

Chief Financial Officer, Executive Vice President

Timothy J. Richmond

Chief Human Resource Officer, Executive Vice President

Key Stats

1.96 mean rating - 24 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

32.7K

2019

33.3K

2020

45.8K

2021(E)

56.3K
EPS (USD)

2018

7.910

2019

8.940

2020

10.560

2021(E)

12.610
Price To Earnings (TTM)
29.43
Price To Sales (TTM)
3.60
Price To Book (MRQ)
15.37
Price To Cash Flow (TTM)
12.51
Total Debt To Equity (MRQ)
653.50
LT Debt To Equity (MRQ)
590.64
Return on Investment (TTM)
5.47
Return on Equity (TTM)
4.49

Latest News

Latest News

U.S. FDA approves AbbVie's migraine prevention drug

AbbVie Inc said on Tuesday the U.S. health regulator approved its once-daily oral medicine for preventive treatment of migraine in adults, adding a third drug to the drugmaker's arsenal of therapies for severe headaches.

U.S. FDA approves AbbVie's migraine prevention drug

AbbVie Inc said on Tuesday the U.S. health regulator approved its once-daily oral medicine for the preventive treatment of migraine in adults, adding a third drug to the drugmaker's bank of products for severe headaches.

UPDATE 3-Regenxbio to receive $370 mln upfront in gene therapy deal with AbbVie

AbbVie will pay $370 million upfront to Regenxbio Inc in a deal to develop and sell an experimental gene therapy for the treatment of chronic retinal diseases, the companies said on Monday.

AbbVie, Regenxbio enter deal to develop retinal disease therapy

AbbVie and Regenxbio Inc have entered a partnership to develop and commercialize RGX-314, a gene therapy candidate for the treatment of chronic retinal diseases, the pharmaceutical companies said on Monday.

U.S. FDA seeks new warnings on arthritis drugs from Pfizer, Lilly and AbbVie

The U.S. drug regulator has asked Pfizer, Eli Lilly & Co and AbbVie to include information about the risks of serious conditions and death from the use of their drugs that belong to a class of treatments known as JAK inhibitors.

Takeda to record 63 billion yen provision, update Q1 results on Irish tax issue

Takeda Pharmaceutical Co said on Monday it will record a provision of about 63 billion yen ($574.56 million) in its financial statements for the first quarter to reflect a decision by Ireland's tax appeals body relating to tax assessment received by company's unit on a break...

AbbVie, Lilly face fresh delays in FDA approval for expanded use of arthritis drugs

AbbVie Inc and ELi Lilly & Co are facing fresh delays in the approval of their respective rheumatoid arthritis drugs for treating chronic skin disease eczema as the U.S. health regulator assesses the new class of treatment over safety concerns.

U.S. Supreme Court rebuffs AbbVie appeal in patent fight involving AndroGel drug

The U.S. Supreme Court on Monday declined to hear AbbVie Inc's challenge to a lower court's decision that it violated federal antitrust law by pursuing a "sham" patent complaint against rival Perrigo Co over AbbVie's blockbuster testosterone replacement drug AndroGel.

U.S. Supreme Court rebuffs AbbVie appeal in patent fight involving AndroGel drug

The U.S. Supreme Court on Monday declined to hear AbbVie Inc's challenge to a lower court's decision that it violated federal antitrust law by pursuing a "sham" patent complaint against rival Perrigo Co over AbbVie's blockbuster testosterone replacement drug AndroGel.

Senate Finance Committee launches probe into AbbVie's tax practices

Senate Finance Committee Chairman Ron Wyden has launched an investigation into AbbVie's international tax practices, saying the drugmaker has avoided paying taxes on U.S. prescription drug sales by shifting its profit overseas.

Lawmakers say AbbVie exploits U.S. patents to protect Humira profits, price hikes

U.S. lawmakers on Tuesday accused the chief executive of AbbVie Inc of profiting from Americans by repeatedly raising U.S. prices on its widely-used Humira rheumatoid arthritis drug while cutting the price abroad.

Alvotech sues to invalidate AbbVie's Humira patent 'minefield'

Iceland-based drugmaker Alvotech hf on Tuesday filed a lawsuit against AbbVie Inc seeking to invalidate dozens of its patents on its arthritis drug Humira, the world's top-selling drug by revenue, and accusing it of extending its monopoly with a "minefield" of patents.

AbbVie expects Botox sales recovery in Europe after U.S. rebound

AbbVie Inc said on Friday it expects demand for cosmetic treatments such as Botox in Europe and Brazil to rebound in the second half of 2021 as restrictions ease and stringent safety measures are put in place.

AbbVie raises full-year profit forecast as Humira fuels sales beat

AbbVie Inc beat Wall Street estimates for first-quarter revenue on Friday and raised its full-year profit forecast, helped by demand for blockbuster rheumatoid arthritis drug Humira and newer treatments such as psoriasis treatment Skyrizi.

BRIEF-WLVBP Says Capsida Announced Multi-Year Collaboration, Option Agreement With Abbvie

* WESTLAKE VILLAGE BIOPARTNERS, VERSANT VENTURES ANNOUNCE LAUNCH OF GENE THERAPY COMPANY CAPSIDA BIOTHERAPEUTICS WITH $50 MILLION SERIES A FINANCING

Pharma and healthcare GCs made millions in 2020

Top lawyers at major pharmaceutical companies Eli Lilly and Co and AbbVie Inc had a lucrative year, new regulatory filings show, with the coronavirus pandemic keeping Big Pharma busy in 2020 even as it wreaked economic havoc elsewhere.

AbbVie requests Supreme Court review of 'sham' patent litigation ruling

AbbVie Inc. has asked the U.S. Supreme Court to review a federal appeals court ruling that it and partner Besins Healthcare Inc. violated antitrust law by filing a "sham" patent complaint to delay a generic version of its blockbuster testosterone replacement drug AndroGel.

U.S. FDA extends review period for expanded use of Abbvie's arthritis drug

Abbvie Inc said the U.S. Food and Drug Administration has extended the review period for expanded use of its rheumatoid arthritis drug Rinvoq by three months, citing the need for more time to assess the drug's benefit-risk profile.

U.S. FDA extends review period for expanded use of Abbvie's arthritis drug

March 17 - The U.S. Food and Drug Administration has extended the review period for expanded use of Abbvie Inc's rheumatoid arthritis drug Rinvoq by three months, the U.S. drugmaker said on Wednesday.

Exclusive: AbbVie in talks to sell $5 billion women's drugs portfolio - sources

U.S. drugmaker AbbVie Inc is in discussions to sell a roughly $5 billion portfolio of women's drugs acquired last year through its $63 billion purchase of Botox maker Allergan Plc, sources familiar with the matter told Reuters.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up